Axovant Sciences Ltd. (AXON) Takes Another Leg Lower

Yesterday's hot IPO for Axovant Sciences Ltd. (NYSE: AXON) took another leg lower mid-day. Shares are now down 18.3%.

As noted yesterday, scrutiny is surrounding the company given that its only product is an abandoned GlaxoSmithKline Alzheimer drug it bought for a mere $5 million. The market cap of the company is around $2B.

You May Also Be Interested In

• Aggreko files for proposed IPO
• Oura said to be seeking up to $3 billion in IPO
• Supreme Court lifts decision that blocked in 23 states and Washington, D.C. Trump's order restricting mail-in ballots